Ascendant Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ascendant Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,500	Closed	-$1.04M	–	82
2022 Q4	$1.04M	Buy	+12,500	New	+$1.01M	3.1%	10

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ascendant Capital Management's XBI Position: Q1 2023 in Review

Ascendant Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 12,500 shares — an estimated $1.04M sold.

Ascendant Capital Management first reported a position in XBI in Q4 2022 and held it in 1 quarter. The position peaked at $1.04M in Q4 2022. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Ascendant Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Ascendant Capital Management sold 12,500 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $1.04M.
Ascendant Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 1 quarter.
Ascendant Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.04M in Q4 2022.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.